Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive Esophagitis (Healing):** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Erosive Esophagitis (Maintenance):** 40 mg orally once daily. Doses of 20 mg orally once daily may be used for maintenance.
* **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Doses of 40 mg orally or intravenously once daily initially. Doses may be adjusted based on clinical response. Doses up to 240 mg intravenously daily have been administered (divided into 30 mg doses every 8 hours).
## Pediatric Dosing
* **GERD (symptomatic):**
* 1 year and older: 15-40 kg: 20 mg orally once daily.
* 1 year and older: greater than 40 kg: 40 mg orally once daily.
* **Erosive Esophagitis:**
* 5 years and older: 20-40 mg orally once daily for up to 8 weeks.
* *Note: Pediatric dosing can vary significantly and should be guided by current institutional protocols and specific patient factors.*
## Dose Adjustments
* **Hepatic Impairment:** Maximum daily oral dose of 40 mg. Intravenous administration is not recommended in patients with severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is typically required.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
* **Serious:** Clostridium difficile-associated diarrhea, bone fracture (hip, wrist, spine), hypomagnesemia (can be severe), vitamin B12 deficiency, lupus erythematosus cutaneus subacutus (SCLE).
## Key Drug Interactions
* **Drugs Dependent on Gastric pH for Absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, and certain HIV protease inhibitors (e.g., atazanavir, nelfinavir). Pantoprazole can decrease absorption.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential interactions with drugs like clopidogrel, although clinical significance may be limited.
## Monitoring
* Magnesium levels, particularly in patients on long-term therapy (>3 months) or those taking concomitant medications like diuretics.
* Bone mineral density if clinically indicated, especially in patients with risk factors for osteoporosis.
* Signs and symptoms of C. difficile infection.
* Vitamin B12 levels with prolonged use.
## Clinical Pearls
* Administer oral pantoprazole 30-60 minutes before a meal.
* For intravenous administration, reconstitute and dilute as per manufacturer instructions. Infuse over 2-15 minutes.
* Long-term PPI use is associated with an increased risk of fractures, C. difficile infection, hypomagnesemia, and vitamin B12 deficiency. Consider the shortest effective duration of therapy.
* Consider switching to oral therapy when clinically appropriate for patients receiving intravenous pantoprazole.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and institutional protocols before making any treatment decisions.*
